Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.


Journal

Kidney & blood pressure research
ISSN: 1423-0143
Titre abrégé: Kidney Blood Press Res
Pays: Switzerland
ID NLM: 9610505

Informations de publication

Date de publication:
2019
Historique:
received: 14 02 2019
accepted: 10 03 2019
pubmed: 12 6 2019
medline: 7 1 2020
entrez: 12 6 2019
Statut: ppublish

Résumé

Matrix metalloproteinases (MMPs) are endopeptidases within the metzincin protein family that not only cleave extracellular matrix (ECM) components, but also process the non-ECM molecules, including various growth factors and their binding proteins. MMPs participate in cell to ECM interactions, and MMPs are known to be involved in cell proliferation mechanisms and most probably apoptosis. These proteinases are grouped into six classes: collagenases, gelatinases, stromelysins, matrilysins, membrane type MMPs, and other MMPs. Various mechanisms regulate the activity of MMPs, inhibition by tissue inhibitors of metalloproteinases being the most important. In the kidney, intrinsic glomerular cells and tubular epithelial cells synthesize several MMPs. The measurement of circulating MMPs can provide valuable information in patients with kidney diseases. They play an important role in many renal diseases, both acute and chronic. This review attempts to summarize the current knowledge of MMPs in the kidney and discusses recent data from patient and animal studies with reference to specific diseases. A better understanding of the MMPs' role in renal remodeling may open the way to new interventions favoring deleterious renal changes in a number of kidney diseases.

Identifiants

pubmed: 31185475
pii: 000499876
doi: 10.1159/000499876
doi:

Substances chimiques

Tissue Inhibitor of Metalloproteinases 0
Matrix Metalloproteinases EC 3.4.24.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

298-330

Informations de copyright

© 2019 The Author(s) Published by S. Karger AG, Basel.

Auteurs

Oskar Zakiyanov (O)

Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia, oskar.zakiyanov@lf1.cuni.cz.

Marta Kalousová (M)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.

Tomáš Zima (T)

Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.

Vladimír Tesař (V)

Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH